LILLY FDA Approval NDA 020592

NDA 020592

LILLY

FDA Drug Application

Application #020592

Documents

Letter2003-07-28
Letter2004-01-22
Letter2006-09-18
Letter2006-02-22
Letter2005-09-15
Letter2006-03-01
Letter2010-01-26
Letter2007-07-10
Letter2008-08-19
Letter2010-06-03
Letter2014-12-23
Letter2013-07-30
Label2004-01-22
Label2006-02-22
Label2006-02-22
Label2009-12-10
Label2009-12-10
Label2007-07-10
Label2007-07-10
Label2010-12-04
Label2011-06-29
Label2015-01-09
Label2013-07-30
Review2007-11-19
Review2007-04-11
Review2009-09-16
Review2009-09-16
Review2012-03-16
Review2011-06-30
Review2012-01-27
Letter2005-06-29
Letter2005-08-08
Letter2006-02-22
Letter2006-12-28
Letter2010-01-26
Letter2007-07-10
Letter2009-11-19
Letter2010-02-01
Letter2010-06-03
Letter2010-12-06
Letter2011-06-27
Letter2011-06-27
Label2003-07-10
Label2006-08-29
Label2006-02-28
Label2006-12-04
Label2009-03-20
Label2009-09-17
Label2010-01-29
Label2010-06-03
Label2010-06-03
Label2011-06-29
Label2015-07-24
Review2004-04-15
Review2007-07-06
Review2012-03-16
Review2011-06-30
Review2012-03-16
Review2012-03-16
Other Important Information from FDA2011-12-22
Other2011-01-07
Letter2016-10-14
Label2016-10-07
Label2017-02-27
Label2017-02-27
Letter2017-03-02
Letter2017-03-02
Pediatric Medical Review1900-01-01
Pediatric Medical Review1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Statistical Review1900-01-01
Pediatric Written Request1900-01-01
Label2018-03-28
Letter2018-03-29
Letter2019-10-23
Label2019-10-24
Medication Guide2019-10-24
Letter2020-04-22
Label2020-04-22
Medication Guide2020-04-22
Label2020-04-24
Medication Guide2020-04-24
Letter2020-04-24

Application Sponsors

NDA 020592LILLY

Marketing Status

Prescription001
Prescription002
Prescription003
Prescription004
Prescription005
Prescription006

Application Products

001TABLET;ORAL2.5MG1ZYPREXAOLANZAPINE
002TABLET;ORAL5MG1ZYPREXAOLANZAPINE
003TABLET;ORAL7.5MG1ZYPREXAOLANZAPINE
004TABLET;ORAL10MG1ZYPREXAOLANZAPINE
005TABLET;ORAL15MG1ZYPREXAOLANZAPINE
006TABLET;ORAL20MG1ZYPREXAOLANZAPINE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP1996-09-30STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL3AP1997-04-18STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL4AP1997-09-09STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL5AP1997-12-04STANDARD
EFFICACY; EfficacySUPPL6AP2000-03-17STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL7AP1998-03-23STANDARD
LABELING; LabelingSUPPL10AP1999-01-11STANDARD
EFFICACY; EfficacySUPPL11AP2000-11-09STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL14AP2001-03-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL16AP2002-01-22STANDARD
EFFICACY; EfficacySUPPL18AP2003-07-10STANDARD
EFFICACY; EfficacySUPPL19AP2004-01-14STANDARD
LABELING; LabelingSUPPL20AP2005-06-29STANDARD
LABELING; LabelingSUPPL26AP2005-08-03STANDARD
LABELING; LabelingSUPPL27AP2006-02-16STANDARD
LABELING; LabelingSUPPL29AP2006-08-25STANDARD
LABELING; LabelingSUPPL32AP2006-02-16STANDARD
LABELING; LabelingSUPPL34AP2005-09-13STANDARD
LABELING; LabelingSUPPL35AP2006-02-23STANDARD
LABELING; LabelingSUPPL38AP2006-11-29STANDARD
EFFICACY; EfficacySUPPL39AP2009-03-19PRIORITY
EFFICACY; EfficacySUPPL40AP2009-12-04PRIORITY
EFFICACY; EfficacySUPPL41AP2009-12-04PRIORITY
LABELING; LabelingSUPPL42AP2007-07-06STANDARD
LABELING; LabelingSUPPL43AP2007-07-06STANDARD
LABELING; LabelingSUPPL49AP2008-08-14STANDARD
LABELING; LabelingSUPPL51AP2009-08-31901 REQUIRED
LABELING; LabelingSUPPL52AP2010-01-27UNKNOWN
LABELING; LabelingSUPPL53AP2010-05-27UNKNOWN
LABELING; LabelingSUPPL55AP2010-05-27UNKNOWN
LABELING; LabelingSUPPL57AP2010-12-01901 REQUIRED
REMS; REMSSUPPL60AP2011-06-21N/A
REMS; REMSSUPPL61AP2011-06-21N/A
LABELING; LabelingSUPPL62AP2014-12-19STANDARD
EFFICACY; EfficacySUPPL63AP2013-07-26STANDARD
LABELING; LabelingSUPPL64AP2015-07-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL65AP2013-10-21STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL66AP2013-10-25STANDARD
LABELING; LabelingSUPPL67AP2016-10-06901 REQUIRED
LABELING; LabelingSUPPL68AP2017-02-23STANDARD
LABELING; LabelingSUPPL69AP2017-02-23901 REQUIRED
LABELING; LabelingSUPPL71AP2018-03-27STANDARD
LABELING; LabelingSUPPL72AP2019-10-22STANDARD
LABELING; LabelingSUPPL74AP2020-04-23STANDARD
LABELING; LabelingSUPPL75AP2020-04-21901 REQUIRED

Submissions Property Types

SUPPL1Null0
SUPPL3Null0
SUPPL4Null0
SUPPL5Null0
SUPPL7Null0
SUPPL14Null0
SUPPL16Null0
SUPPL39Null7
SUPPL40Null26
SUPPL41Null7
SUPPL42Null4
SUPPL51Null7
SUPPL52Null7
SUPPL53Null6
SUPPL55Null6
SUPPL57Null7
SUPPL60Null6
SUPPL61Null6
SUPPL62Null6
SUPPL63Null6
SUPPL64Null7
SUPPL65Null0
SUPPL66Null0
SUPPL67Null15
SUPPL68Null6
SUPPL69Null7
SUPPL71Null7
SUPPL72Null33
SUPPL74Null7
SUPPL75Null7

TE Codes

001PrescriptionAB
002PrescriptionAB
003PrescriptionAB
004PrescriptionAB
005PrescriptionAB
006PrescriptionAB

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 20592
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.